Advertisement

Peritoneal Surface Oncology in Singapore

  • Joey Wee-Shan Tan
  • Melissa Ching Ching TeoEmail author
Original Article

Abstract

Peritoneal surface malignancy is now an established indication for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The landscape of treatment in Singapore has evolved through the years, with expanded indications as the experience in the management of this disease improves.

Keywords

Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Singapore 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefGoogle Scholar
  2. 2.
    Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, François Y, Vignal J, Gilly FN (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869CrossRefGoogle Scholar
  3. 3.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116:5608–5618CrossRefGoogle Scholar
  4. 4.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O (2016) What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113:796–803CrossRefGoogle Scholar
  5. 5.
    Levine EA, Stewart JH IV, Shen P, Russell GB, Loggie BL, Votanopoulos KI (2014) Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 218:573–585CrossRefGoogle Scholar
  6. 6.
    Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, Cotte E (2014) Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol 40:529–535CrossRefGoogle Scholar
  7. 7.
    Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK (2014) Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg 31:334–340CrossRefGoogle Scholar
  8. 8.
    Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRefGoogle Scholar
  9. 9.
    Bartlett EK, Meise C, Roses RE, Fraker DL, Kelz RR, Karakousis GC (2014) Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database. Ann Surg Oncol 21:1494–1500CrossRefGoogle Scholar
  10. 10.
    Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14:253CrossRefGoogle Scholar
  11. 11.
    Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 20:367–373CrossRefGoogle Scholar
  12. 12.
    Ministry of Health. “MediSave”. https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/medisave. Accessed 5 December 2018
  13. 13.
    Ministry of Health. “MediShield Life”. https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/medishield-life. Accessed 5 December 2018
  14. 14.
    Ministry of Health. “MediFund”. https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/medifund. Accessed 5 December 2018
  15. 15.
    Chin F (2013) Inside the Singapore medical system. Int J Radiat Oncol Biol Phys 87:864–866CrossRefGoogle Scholar
  16. 16.
    Ministry of Health. “The social and health manpower development programme (SHMDP)”. https://www.moh.gov.sg/hpp/doctors/programmes/ProgrammeDetails/social-health-manpower-development-programme-shmdp. Accessed 5 December 2018
  17. 17.
    National Cancer Centre Singapore. “2nd Peritoneal Surface Malignancy Course 2018”. http://psmconference.org/. Accessed 5 December 2018
  18. 18.
    National University of Singapore. “2nd Asia-Pacific PIPAC Workshop & Symposium on Peritoneal Cancers”. http://medicine.nus.edu.sg/medsur/pipac/index.html. Accessed 5 December 2018
  19. 19.
    Tan G et al (2016) 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperth:1–7Google Scholar
  20. 20.
    Teo M, Soo KC (2016) National Cancer Center Singapore: the way forward. Future Oncol (London) 12:433–437CrossRefGoogle Scholar
  21. 21.
    Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, Morris DL (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol 14:2270–2280CrossRefGoogle Scholar
  22. 22.
    Kuijpers AM, Hauptmann M, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Verwaal VJ (2016) Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol 42:244–250CrossRefGoogle Scholar
  23. 23.
    Smeenk RM, Verwaal VJ, Zoetmulder FAN (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414CrossRefGoogle Scholar
  24. 24.
    Shannon BN, et al. Biphasic learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:technical competence and refinement of patient selection. 2018Google Scholar
  25. 25.
    Desantis M, Bernard JL, Casanova V, Cegarra-Escolano M, Benizri E, Rahili AM, Benchimol D, Bereder JM (2015) Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck's Arch Surg 400:37–48CrossRefGoogle Scholar
  26. 26.
    Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Cancer 106:1144–1153CrossRefGoogle Scholar
  27. 27.
    Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, Zhao J, Morris DL (2010) Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg 251:101–106CrossRefGoogle Scholar
  28. 28.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42CrossRefGoogle Scholar
  29. 29.
    Seo CJ et al (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: unconvention indications. EC Cancer 1(1):12–20Google Scholar
  30. 30.
    Tan GH et al (2013) Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singap 42:291–296Google Scholar
  31. 31.
    Chen L, Teo M (2017) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent leiomyosarcoma with peritoneal sarcomatosis: a case report and review of the literature. J Cases Obstet Gynecol 4(1):6–10Google Scholar
  32. 32.
    Yee FZY et al (2017) Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Pleura Peritoneum 2(3):129–136CrossRefGoogle Scholar
  33. 33.
    Wong JF et al (2015) Repeat cytoreductive surgery and HIPEC for peritoneal surface malignancy and peritoneal carcinomatosis. World J Surg 39:1578–1583CrossRefGoogle Scholar
  34. 34.
    Wang W, Tan GHC, Skanthakumar T, Chia CS, Soo KC, Teo MCC (2018) Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre programme in peritoneal disease. Int J Hyperth 34:551–558CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Division of Surgical Oncology, National Cancer Centre SingaporeSingaporeSingapore

Personalised recommendations